Evaluation of Fisetin to Reduce Systemic Senescence
Evaluation of Fisetin to Reduce Systemic Senescence Indices: A Randomized Controlled Dosing Equivalence Study
This is a prospective, randomized clinical trial to evaluate the ability of the supplement, Fisetin, to safely reduce systemic senescence (aging) indices assessed in peripheral blood.
研究概览
地位
地位
干预/治疗
干预/治疗
详细说明
This is a prospective, randomized clinical trial designed to examine the effect of two different Fisetin dosing schedules on peripheral blood cells and biomarkers related to aging as well as the occurrence of side effects. The purpose of this study is to evaluate the ability of the supplement, Fisetin, to safely reduce systemic senescence (aging) indices assessed in peripheral blood. 96 healthy volunteers will be randomized into one of two arms (1:1). Group 1 - n= 48: Fisetin Daily Dosing; Group 2 - n=48: Fisetin Bolus Dosing.
研究类型
研究类型
注册 (实际的)
注册
阶段
阶段
- 阶段2
- 阶段1
联系人和位置
学习地点
-
-
Colorado
-
Vail、Colorado、美国、81657
- Steadman Philippon Research Institute
-
-
参与标准
资格标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Adults ≥55 years of age;
- Capacity to personally give informed consent (consent via legally authorized representative will not be accepted);
- Willing to comply with all study procedures and assessments.
Exclusion Criteria:
-
Within 2 years of signing informed consent history of active blood disorders (i.e., DVTs, chronic blood clotting, hemophilia, leukemia, myeloma, etc.); or active malignancy of any type or history of a malignancy (with the exception of Subjects with a history of treated basal or squamous cell carcinoma);
-
Females who are nursing a child, are pregnant, or are planning to become pregnant during drug dosing;
-
Males who do not wish to abstain from sex with women of childbearing potential without use of contraceptive protection by either party during drug dosing;
-
Any significant illness within the last 30 days requiring clinical care, and/or any medications, medical condition, including findings in medical history or in the baseline assessments that, in the opinion of the Principal Clinical Investigator or the screening clinician, constitutes a risk or contraindication for participation in the study or that could interfere with the study conduct, endpoint evaluation, or prevent the subject from fully participating in all aspects of the study;
-
Allergy to any active or inactive ingredient of Fisetin, and/or taking medication with known Fisetin interaction;
-
Subjects with any of the following drug/medication statuses:
- Taking medications that affect insulin activity, including Metformin or Acarbose, within one week of signing informed consent;
- Currently taking Warfarin or related anticoagulants;
- Currently taking Lithium;
- Senolytic agents taken within the past 3 months and are not willing to discontinue these medications through the duration of the study, including: Fisetin, Quercetin, Luteolin, Dasatinib, Piperlongumine, or Navitoclax;
- Taking drugs that induce significant cellular stress and are not willing to discontinue these medications through the duration of the study, including alkylating agents, anthracyclines, platins, and other chemotherapy drugs;
- Taking the following drugs if they cannot be held (per the Principal Investigator) for at least 2 days before and during administration of Fisetin: cyclosporine, tacrolimus, repaglinide, and bosentan;
- Taking a glucocorticoid within 1 month of signing informed consent;
- Currently taking phenytoin or nateglinide;
-
PHQ-9 - Patient Health Questionnaire - total score exceeds 9;
-
Inability to tolerate oral medication;
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
手臂数量
武器和干预
参与者组/臂参与者组/臂 |
干预/治疗干预/治疗 |
|---|---|
|
实验性的:Fisetin (daily dosing)
A single Fisetin 100mg capsule will be taken daily for 60 days. |
Oral Fisetin 100mg capsule
其他名称:
|
|
实验性的:Fisetin (bolus dosing)
Fisetin 100 mg capsules (~20 mg/ kg/ day) will be administered orally for two consecutive days (days 1 and 2) followed by 28 days off. This cycle of 2 dosing days followed by 28 days off will repeat for a total of 2 cycles, or 4 dosing days total. Dosing days will occur on days 1&2, and 31&32. |
Oral Fisetin 100mg capsule, dosed at 20 mg/kg
其他名称:
|
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change from baseline in levels of senescent PBMCs (total and specific PBMC subsets such as T-Cells)
大体时间:Baseline, Visit 4 (45 days)
|
Cell types measured via flow cytometry and analyzed via immunophenotype and senescent panels. |
Baseline, Visit 4 (45 days)
|
次要结果测量
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change from baseline in levels of senescent PBMCs (total and specific PBMC subsets such as T-Cells)
大体时间:Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 5 (60 days)
|
Cell types measured via flow cytometry and analyzed via immunophenotype and senescent panels. |
Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 5 (60 days)
|
|
Change from baseline in senescence-related serum biomarkers
大体时间:Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)
|
Concentrations of proteins related to senescence will be analyzed using multiplex immunoassays and ELISA from serum/plasma. |
Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)
|
|
Number of participants experiencing one or more treatment-emergent adverse events
大体时间:From date of study drug dosing until the end of the study, an average of 2 months
|
Number of participants experiencing one or more treatment-emergent adverse events |
From date of study drug dosing until the end of the study, an average of 2 months
|
|
Perturbations in senescent PBMC values
大体时间:Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)
|
Cell types measured via flow cytometry and analyzed via immunophenotype and senescent panels. |
Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)
|
|
Perturbations in senescent serum/plasma biomarkers values
大体时间:Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)
|
The variability over visits of serum/plasma concentrations of proteins related to senescence will be assessed using multiplex immunoassay and ELISA. |
Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)
|
合作者和调查者
调查人员
调查人员
- 首席研究员:Johnny Huard, PhD、Steadman Philippon Research Institute
研究记录日期
研究主要日期
学习开始 (实际的)
学习开始
初级完成 (实际的)
初级完成
研究完成 (实际的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (实际的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.